Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas-Reference-Cited by-同舟云学术

Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas

Published:2018-02-22 Issue:4 Volume:178 Page:
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Maroñas‐Jiménez L.¹^ORCID,Estrach T.²,Gallardo F.³,Pérez A.⁴,Andrés Borja H.⁵,Servitje O.⁶,Pérez Gala S.⁷,Linares Barrio M.⁸,Jiménez Gallo D.⁸,Sanz‐Bueno J.⁹,Lora D.¹⁰,Monsálvez V.¹,Ortiz‐Romero P.L.¹

Affiliation:

1. Department of Dermatology Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense Madrid Spain

2. Department of Dermatology Hospital Clínic‐Universitat de Barcelona IDIBAPS Barcelona Spain

3. Department of Dermatology Hospital Del Mar Barcelona Spain

4. Department of Dermatology Hospital General Universitario de Valencia Valencia Spain

5. Department of Dermatology Hospital Universitario Donostia San Sebastián Spain

6. Department of Dermatology Hospital Universitario de Bellvitge Barcelona Spain

7. Department of Dermatology Hospital Universitario Ramón y Cajal Madrid Spain

8. Department of Dermatology Hospital Universitario Puerta del Mar Cádiz Spain

9. Department of Dermatology Hospital Universitario Rey Juan Carlos Madrid Spain

10. Clinical Research Unit IMAS12‐CIBERESP Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense Madrid Spain

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.16128

Reference8 articles.

1. Aprepitant as an Antipruritic Agent?

2. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma

3. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues

4. Aprepitant: A novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma

5. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T‐cell lymphoma;Borja‐Consigliere HA;Actas Dermosifiliogr,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. After 20 Years of Treatment with Aprepitant for Chemotherapy-Induced Nausea and Vomiting, Should the Therapeutic Indications for Aprepitant be Expanded?;Pakistan Journal of Health Sciences;2024-06-30

2. Advances in the research and application of neurokinin-1 receptor antagonists;Journal of Zhejiang University-SCIENCE B;2024-02

3. What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus;American Journal of Clinical Dermatology;2023-11-16

4. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma;Clinical and Experimental Medicine;2023-08-09

5. A systematic review on the management of pruritus in patients with cutaneous T-cell lymphoma;Itch;2021-04